Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01879995
Other study ID # KEK-ZH-Nr. 2013-0120
Secondary ID
Status Completed
Phase N/A
First received June 4, 2013
Last updated February 5, 2016
Start date June 2013
Est. completion date July 2015

Study information

Verified date February 2016
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority Switzerland: Swissmedic
Study type Observational

Clinical Trial Summary

The mainstay of PKU treatment is a low-phenylalanine diet (i.e restriction of natural protein), and supplementation with a protein substitute (a mixture of amino acids free from phenylalanine, also containing micronutrients and vitamins) and special low-protein foods, to meet the patient's energy requirements. When diet and treatment is relaxed after childhood, adult and adolescent patients with phenylketonuria are at risk for malnutrition, depending on the compliance with treatment and the intake of amino acid supplements.

In this study, nutrition status of patients with PKU and hyperphenylalaninemia is systematically assessed under ongoing current treatment, in relation to Phe-tolerance, compliance with treatment, and psychosocial issues.

Study participants do not undergo any specific therapeutic or diagnostic intervention.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group 16 Years and older
Eligibility Inclusion criteria:

- PKU (Phenylketonuria) or hyperphenylalaninemia

- male or female, minimum age 16y

- signed informed consent

Exclusion criteria:

- patient who can not comply with the study protocol (e.g. unable to fill in questionnaires by themselves or a representative)

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Locations

Country Name City State
Switzerland University Children's Hospital Zurich
Switzerland University Hospital Zurich, Division of Endocrinology, Diabetes and Clinical Nutrition Zurich ZH

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Macronutrient and micronutrient intake, calculated from a nutrition protocol (four consecutive days) Assessed nutrients:
Macronutrients: protein, fat, carbohydrates in g/kg/d
Daily phenylalanine and tyrosine intake Micronutrients and minerals: Calcium, magnesium, iron, zinc, selenium
Vitamins: D, B12, B6, C, folic acid
assessed during 4 consecutive days max. within 1 month after a regular consultation in the outpatient clinic No
Secondary Phenylalanine level (umol/l) this outcome measure is not study-specific and is collected as part of established routine care (self-measurement by patient) assessed at the end of the four-day nutrition protocol (see primary outcome) No
Secondary Plasma amino acid profile this outcome measure is not study-specific and is collected as part of established routine care. determined at a routine visit at the outpatient clinic, on average 1x per year No
Secondary Concentrations of micronutrients, minerals and vitamins assessed parameters: Ferritin, zinc, selenium, vitamin D, vitamin B12, folic acid.
These outcome measures are not study-specific and are collected as part of established routine care
determined at a routine visit at the outpatient clinic, on average 1x per year No
Secondary body weight (kg) assessed as part of routine clinical care determined at a routine visit at the outpatient clinic, on average once every 6 - 12 months No